H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma (TRAW) with a Buy rating and $8 price target The company’s pipeline is led by two oral antivirals, ratutrelvir in development for COVID-19, and tivoxavir marboxil for seasonal and avian influenza, the analyst tells investors in a research note. The firm believes Traws has the potential to unlock value for shareholders if the company is able to replicate the strong early stage data.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW: